New York Launches First State-Led Cannabis Study on IBD Patients

New York has become the first state in the nation to design and launch its own clinical cannabis study, and the target condition is one that affects roughly three million Americans. The New York State Office of Cannabis Management announced a pilot observational study examining how oral doses of CBD and THC impact quality of life in adults diagnosed with moderate inflammatory bowel disease. It is a move that could reshape how state regulators approach cannabis research across the country.

Inside the Study Design

The study, formally titled "A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms," targets a patient population that has long reported anecdotal benefits from cannabis but has lacked rigorous, state-backed data to support those claims.

Participants must be at least 18 years old with a clinically confirmed IBD diagnosis — encompassing both Crohn's disease and ulcerative colitis — whose symptoms are not adequately managed by their current prescribed treatment regimens. This is an important detail: the study isn't looking at cannabis as a first-line therapy but as a supplementary option for patients who have already tried conventional treatments without sufficient relief.

Enrolled participants will self-administer daily oral doses of CBD and THC over the study period, with researchers tracking symptom severity, quality of life measures, and any adverse effects. Smokable forms of marijuana are explicitly excluded — participants must abstain from smoking cannabis for the duration, ensuring that the data reflects the impact of controlled oral dosing rather than varied consumption methods.

To remove financial barriers, participants will receive vouchers covering the cost of their medical cannabis products from licensed dispensaries.

Why This Study Matters

The significance of this study goes beyond its specific findings about IBD. It represents the first time a state cannabis regulatory agency has designed and launched a medical study — not just funded one, not just partnered with a university, but actually served as the driving force behind the research design and implementation.

This matters because cannabis research has historically been hampered by its Schedule I classification under federal law, which restricted the types of studies researchers could conduct and the quality of cannabis they could use. While the April 2026 rescheduling of state-licensed medical marijuana to Schedule III has eased some of those restrictions, states have generally left clinical research to universities and private institutions.

New York's approach signals a potential new model where state regulators don't just oversee cannabis markets but actively generate the evidence base that informs medical policy. If the study produces meaningful results, other states with established cannabis offices may follow suit with their own condition-specific research programs.

The IBD Connection

Inflammatory bowel disease is a compelling target for cannabis research. The condition, which includes Crohn's disease and ulcerative colitis, involves chronic inflammation of the gastrointestinal tract and affects an estimated 3.1 million adults in the United States. Symptoms include severe abdominal pain, persistent diarrhea, fatigue, and unintended weight loss, and the condition can significantly impair quality of life.

The endocannabinoid system plays a well-documented role in gut function and immune regulation. CB1 and CB2 receptors are present throughout the gastrointestinal tract, and preclinical research has shown that cannabinoids can modulate intestinal inflammation, reduce gut motility, and influence pain signaling in the digestive system.

Survey data has consistently shown high rates of cannabis use among IBD patients. A study published in the journal Inflammatory Bowel Diseases found that up to 15 percent of IBD patients use cannabis to manage their symptoms, with the majority reporting improvements in abdominal pain, appetite, nausea, and diarrhea. However, these findings have been largely self-reported and observational, lacking the controlled conditions needed to draw clinical conclusions.

New York's study aims to bridge that gap by collecting standardized data on symptom outcomes under controlled dosing protocols.

Partnership With Licensed Providers

The study leverages New York's existing medical cannabis infrastructure through partnerships with licensed providers. Vireo Health, Rise Dispensaries, and Citiva Medical are participating as product suppliers, providing regulated cannabis products to study participants through the state's dispensary network.

This partnership model has practical advantages. Rather than navigating the complex process of obtaining research-grade cannabis through federal channels — historically supplied exclusively by the University of Mississippi — the study uses commercially available, state-regulated products that patients would actually access in a real-world medical cannabis program.

The approach also means the study's findings will be directly applicable to the products patients can purchase, rather than reflecting outcomes from specially formulated research compounds that differ from what is available at dispensaries.

What Previous Research Shows

New York's study builds on a growing but still incomplete evidence base. Over 100 notable cannabis studies have been published in 2026 alone, covering applications from pain management to cancer therapy. Several specifically address gastrointestinal conditions.

A 2023 systematic review published in Cannabis and Cannabinoid Research found that cannabis-based interventions showed promise for reducing abdominal pain and improving overall well-being in IBD patients, but noted that small sample sizes and methodological variations limited the strength of conclusions.

More recently, a 2025 randomized controlled trial from Israel found that cannabis-rich botanical extract improved clinical remission rates in patients with active Crohn's disease compared to placebo, though the authors emphasized the need for larger, longer-term studies.

The New York study's observational design — tracking real patients using commercially available products over an extended period — could provide exactly the kind of real-world evidence that previous smaller studies have called for.

Implications for Patients and Policy

For the estimated 230,000 New Yorkers living with IBD, the study represents both a practical opportunity and a symbolic recognition. Participants gain access to voucher-covered medical cannabis products while contributing to research that could inform future treatment guidelines. And the study's mere existence validates what many IBD patients have been saying for years: cannabis helps, and the medical establishment should be taking that seriously.

On the policy front, the study could influence how New York and other states evaluate qualifying conditions for medical cannabis programs. If the data supports meaningful symptom improvement, it strengthens the case for including IBD as a standard qualifying condition in states where it is not currently listed.

The study also sets a precedent for how state cannabis offices can contribute to the broader medical evidence base. With over $1 billion in annual cannabis tax revenue flowing into state coffers nationwide, advocates have argued that states have both the resources and the obligation to invest in rigorous cannabis research. New York is now testing that proposition directly.

How to Participate

Prospective participants can find enrollment information at cannabis.ny.gov. Eligibility requires an IBD diagnosis, current enrollment in New York's medical cannabis program, and willingness to adhere to the study protocol, including abstaining from smokable cannabis during the study period. The study is actively recruiting as of June 2026.

For IBD patients who have been managing their symptoms with cannabis on their own, the study offers a chance to contribute to the science while receiving free products. For the cannabis research community, it offers something potentially more valuable: a state-backed model for generating the clinical data that has been missing for too long.